Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
IPCA LABS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IPCA LABS Mar-23 |
ADCOCK INGRAM Jun-14 |
IPCA LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,062 | 319 | - | |
Low | Rs | 768 | 230 | - | |
Sales per share (Unadj.) | Rs | 243.0 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 19.4 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 29.7 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 230.3 | 74.5 | - | |
Shares outstanding (eoy) | m | 253.70 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.8 | 2.9 | 130.1% | |
Avg P/E ratio | x | 47.2 | -11.5 | -410.9% | |
P/CF ratio (eoy) | x | 30.8 | -13.9 | -222.3% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 107.8% | |
Dividend payout | % | 20.6 | 0 | - | |
Avg Mkt Cap | Rs m | 232,120 | 46,340 | 500.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 12,876 | 2,908 | 442.7% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 61,642 | 16,016 | 384.9% | |
Other income | Rs m | 1,518 | 112 | 1,353.2% | |
Total revenues | Rs m | 63,160 | 16,128 | 391.6% | |
Gross profit | Rs m | 9,033 | -2,775 | -325.4% | |
Depreciation | Rs m | 2,616 | 691 | 378.4% | |
Interest | Rs m | 482 | 434 | 111.1% | |
Profit before tax | Rs m | 7,453 | -3,788 | -196.7% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,534 | 237 | 1,070.3% | |
Profit after tax | Rs m | 4,919 | -4,036 | -121.9% | |
Gross profit margin | % | 14.7 | -17.3 | -84.6% | |
Effective tax rate | % | 34.0 | -6.2 | -544.0% | |
Net profit margin | % | 8.0 | -25.2 | -31.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 51,893 | 11,730 | 442.4% | |
Current liabilities | Rs m | 18,058 | 6,600 | 273.6% | |
Net working cap to sales | % | 54.9 | 32.0 | 171.4% | |
Current ratio | x | 2.9 | 1.8 | 161.7% | |
Inventory Days | Days | 51 | 111 | 46.2% | |
Debtors Days | Days | 6 | 124 | 4.7% | |
Net fixed assets | Rs m | 34,336 | 6,838 | 502.2% | |
Share capital | Rs m | 254 | 74 | 341.2% | |
Net worth | Rs m | 58,420 | 12,571 | 464.7% | |
Long term debt | Rs m | 6,518 | 4,418 | 147.5% | |
Total assets | Rs m | 86,229 | 23,747 | 363.1% | |
Interest coverage | x | 16.5 | -7.7 | -212.9% | |
Debt to equity ratio | x | 0.1 | 0.4 | 31.7% | |
Sales to assets ratio | x | 0.7 | 0.7 | 106.0% | |
Return on assets | % | 6.3 | -15.2 | -41.3% | |
Return on equity | % | 8.4 | -32.1 | -26.2% | |
Return on capital | % | 12.2 | -19.8 | -61.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,058 | 1,367 | 589.4% | |
From Investments | Rs m | -7,250 | -420 | 1,727.2% | |
From Financial Activity | Rs m | 5,072 | 4,009 | 126.5% | |
Net Cashflow | Rs m | 5,881 | 4,957 | 118.6% |
Compare IPCA LABS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare IPCA LABS With: LINK PHARMA FREDUN PHARMA BHARAT PARENTALS J.B.CHEMICALS ORTIN LABS
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.